Another mechanism by which PCSK9 can modulate the migration of monocytes is the chemokine receptor type-2, which was inhibited by PCSK9 inhibitors in patients with familial hypercholesterolemia and decreased the capacity of monocytes to pass the endothelium [85]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.